Avadel Pharmaceuticals plc (AVDL) concluded trading on Thursday at a closing price of $15.47, with 5.11 million shares of worth about $79.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.46% during that period and on October 31, 2024 the price saw a gain of about 19.83%. Currently the company’s common shares owned by public are about 96.27M shares, out of which, 90.35M shares are available for trading.
Stock saw a price change of 19.00% in past 5 days and over the past one month there was a price change of 18.45%. Year-to-date (YTD), AVDL shares are showing a performance of 9.56% which increased to 56.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.69 but also hit the highest price of $19.09 during that period. The average intraday trading volume for Avadel Pharmaceuticals plc shares is 876.84K. The stock is currently trading 17.00% above its 20-day simple moving average (SMA20), while that difference is up 12.56% for SMA50 and it goes to 1.47% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (NASDAQ: AVDL) currently have 96.27M outstanding shares and institutions hold larger chunk of about 71.93% of that.
The stock has a current market capitalization of $1.49B and its 3Y-monthly beta is at 1.50. It has posted earnings per share of -$1.15 in the same period. It has Quick Ratio of 2.52 while making debt-to-equity ratio of 0.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AVDL, volatility over the week remained 4.78% while standing at 4.11% over the month.
Stock’s fiscal year EPS is expected to rise by 74.19% while it is estimated to increase by 218.16% in next year. EPS is likely to grow at an annualized rate of 15.00% for next 5-years, compared to annual growth of 4.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on June 12, 2024 offering a Buy rating for the stock and assigned a target price of $27 to it. Coverage by Oppenheimer stated Avadel Pharmaceuticals plc (AVDL) stock as an Outperform in their note to investors on March 05, 2024, suggesting a price target of $29 for the stock. On March 05, 2024, Needham Reiterated their recommendations, while on March 05, 2024, H.C. Wainwright Reiterated their ratings for the stock with a price target of $25. Stock get a Buy rating from UBS on February 06, 2024.
